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Abstract
Background: Ovarian clear cell carcinoma (CCC) is an uncommon subtype of ovarian epithelial tumor. The prognostic
significance of its clinicopathological parameters is discordant, with the exception of stage as the adverse prognostic
factor. The present study aimed to evaluate the prognostic significance of its clinicopathological characteristics and
the expression of IMP3 (Insulin-like growth factor-II mRNA-binding protein 3, IMP3 or IGF2BP3) in Chinese patients
with primary pure CCC.
Methods: We collected clinicopathological data from 73 cases with a minimum of 5 years of follow-up and evaluated
the expression of IMP3 by immunohistochemistry.
Results: In total, 49.3 % of the patients were in stage I. Advanced stages were closely related to poor prognosis of
disease-free survival (DFS) and overall survival (OS) (P < 0.005). Patients with CCC coexisting with endometriosis tended
to be younger and to have unilateral involvement but did not exhibit differences in prognosis compared with patients
with CCC without endometriosis. Other histological features such as growth pattern, mitosis, and necrosis did not have
prognostic significance. IMP3 was positive in 63 % of patients (46 of 73 cases); Thus, positive expression of IMP3 is an
adverse prognostic marker in terms of OS (P = 0.012), even in stage I patients (P = 0.038).
Conclusions: The present study demonstrates that IMP3 expression is a prognostic marker, with the exception of
stage. IMP3 represents a biomarker of unfavorable prognosis even in stage I patients.
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Background
The prevalence of ovarian clear cell carcinoma (CCC),
which has significant geographic differences, accounts
for 5–25 % of cases in various countries [1, 2]. Most of
CCC in stage I [3] associated with endometriosis [4] has
a poor response to platinum-based regimens, which
results in an unfavorable prognosis, particularly for
advanced stages [3, 5, 6]. The various morphologies of
CCC result in misclassification, which further affects the
assessment of morbidity and prognostic factors. A
grading system based on CCC growth pattern corre-
lates with survival in ovarian CCC [7]. However, this
relationship has not been further confirmed, and the
impact of the histopathological characteristics on
prognosis has been disputed.
Insulin-like growth factor-II mRNA-binding protein 3
(IMP3 or IGF2BP3), a member of the IMP family, is
highly expressed in embryo. This protein is involved in
the binding, transport and stability of the embryonic
isoforms of the IGF-II gene. IMP3 is considered as an
oncofetal protein and is related to tumor metastasis.
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This protein is often found to be overexpressed in many
types of tumors, such as gastric cancer, colorectal cancer,
liver cancer, and pancreatic cancer, where it acts as an
independent prognostic factor [8–11]. However, few
studies have examined the role of IMP3 in gynecologic
tumors, such as in ovarian CCC, endometrial CCC and
cervical squamous carcinomas [12–14]. IMP3 expression
in ovarian CCC was reported in a previous study; how-
ever, subsequent studies with small sample size have not
confirmed the same results [12, 15]. Therefore, the sig-
nificance of IMP3 expression in ovarian cancer, particu-
larly in CCC, requires further analysis.
Few studies of primary pure ovarian CCC have been
examined in Chinese patients and the lack of effective
prognostic indicators in addition to staging. Therefore,
reviewing and understanding the characteristics of CCC
and assessing IMP3 expression as a prognostic param-
eter are of great importance.
Methods
Patients and clinicopathological characteristics
The present study was approved by the Ethical Review
Committee of Fudan University Shanghai Cancer Center.
Data were collected from 73 patients with a primary
diagnosis of pure ovarian CCC who underwent their first
operation at Fudan Cancer Center between 1999 and
2009 and who had a minimum of 5 years of follow-up.
Hematoxylin-eosin (HE)-stained sections were reviewed
by three gynecological pathologists. The patients
underwent total abdominal hysterectomy, bilateral
salpingo-oophorectomy, omentectomy, and appendec-
tomy simultaneously or asynchronously. The patients
were then treated with platinum-based postoperative
chemotherapy. Staging was determined according to
the 2014 FIGO new ovarian, tubal, peritoneal tumor
staging guidelines [16].
Histological morphology was estimated approximately
according to the summary of DeLair et al. [17] for the
determination of tumor growth pattern (tubulocystic,
solid, or papillary), cell type (clear cell, oxyphil cell, hob-
nail cell or columnar cell), mitotic index (10/HPF),
stroma (hyalinized, myxoid, fibroblastic), and necrosis.
We also evaluated the presence of endometriosis (ovar-
ian and/or extra-ovarian) in the specimens.
Immunohistochemistry
IMP3 expression was evaluated by immunohistochemis-
try using the EnVision method [15]. Briefly, sections
(4 μm) were deparaffinized and treated with 0.3 %
hydrogen peroxide, boiled in citrate buffer (pH 6.0) for
15 min, and cooled at room temperature. Sections were
incubated with a primary IMP3 antibody (Clone 69.1,
dilution 1:200, Dako Glostrup, Denmark) at 4 °C over-
night, rinsed in PBS, and then incubated for 40 min with
biotinylated secondary antibody. Sections were stained
in DAB (Dako, Glostrup, Denmark), rinsed three times
in PBS, and then counterstained with hematoxylin. Incu-
bation in PBS buffer in lieu of primary antibody was
used as a negative control, and IMP3 expression in the
germinal center of the lymph node served as a positive
control. We defined positive IMP3 staining as convin-
cing cytoplasmic expression in more than 10 % of tumor
cells [18]. The positive staining intensity was recorded as
weak, moderate, or strong.
Follow-up
The patients were followed up until March 31, 2014.
Overall survival (OS) was defined as the time from oper-
ation to either death or the last follow-up. Disease-free
survival (DFS) was defined as the interval from oper-
ation to disease recurrence or the last follow-up. We
defined disease recurrence as a consistent elevation of
CA125, or observation of tumor by clincial examination
including physical examination and imaging studies [19].
Statistical analyses
The chi-square test and Fisher’s exact test were used to
evaluate the association between IMP3 expression and
multiple clinicopathological parameters. Survival analysis
was determined using Kaplan–Meier univariate analysis.
Differences in survival curves were compared with the
log-rank test. P values < 0.05 were considered significant.
For statistical analyses, SPSS software version 19.0 (IBM
SPSS Statistics 19) was used.
Results
Clinicopathological characteristics
The ages of the 73 patients ranged from 19 to 80 years
old (mean, 53.63 years; median, 54 years). Macroscopic-
ally, the tumor size ranged from 2 to 27 cm (mean,
10.45 cm). Unilateral tumors were the most frequent,
occurring in 58 cases (79.5 %), while bilateral tumors
occurred in 15 cases (20.5 %). The serum level of CA125
was above normal in the 56 preoperative cases (47/56,
83.9 %). Ascites were present in 48.5 % of patients (33/
68) and absent in 51.5 % (35 cases) of patients in the
recorded data. The percentages of cases at each FIGO
stage were as follows: stage I, 49.3 % (36 cases); stage II,
15.1 % (11 cases); stage III, 24.7 % (18 cases) and stage
IV, 11 % (8 cases). Follow-up information was obtained
from 69 patients. The OS of patients ranged from 0.7 to
173.8 months (mean, 61.2 m; median, 59 m), and the
DFS ranged from 0.7 to 173.8 months (mean, 53.2 m;
median, 38.2 m). The 5-year survival rate varied among
stages as follows: stage I (26/33, 78.8 % of cases), stage II
(5/11, 45.5 % of cases), stage III (5/18, 27.8 % of cases),
and stage IV (0/6, 0 % of cases) (P < 0.001).
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Histopathological features were summarized in Table 1.
Basically, ovarian clear cell carcinomas showed a variable
admixture of papillary, tubulocystic and solid growth
pattern. A variable papillary component was present in
82.2 % of cases (60 of 73). Pure papillary pattern, tubulo-
cystic pattern and solid pattern were observed in 34.2 %
(25/73), 6.8 % (5/73) and 2.7 % (2/73) cases respectively.
Mixed papillary and tubulocystic pattern were present in
27.4 % (20/73) cases. Mixed tubulocystic and solid
pattern, mixed papillary and solid were observed in
8.2 % (6 /73) and 8.2 % (6/73) respectively. A mixed
pattern of papillary, tubulocystic and solid were present
in 12.3 % (9/73) cases. Ovarian clear cell carcinomas
were composed by variable proportions of clear cells,
oxyphilic cells, hobnail cells and colunmar cells. Hobnail
cells were present in 56.2 % (41/73) of all cases. A mix-
ture of clear cells and oxyphilic cells was present in
78.1 % (57/73) cases, Pure clear cell type was observed
in 15.1 % (11/73) cases. 6.8 % (5/73) cases composed of
pure oxyphilic cell. Rare cases presented with columnar
cells with subnuclear or supranuclear vacuoles (Fig. 1a).
The mean mitotic index was 4.6/10 HPFs. Mitotic
figures were 0–9/10 high-power fields (HPFs) in 65 cases
(89 %). The remaining cases had more than 10/10HPF,
with the highest of 17/10 HPFs. Diversity was observed
among the stromal changes, including fibrous, hyaline
and myxoid stroma. Pure hyaline or myxoid stroma were
observed in 4 cases (5.5 %) and 1 case (1.4 %) respect-
ively. Focal or patchy necrosis was observed in 39.7 %
(29/73) of the cases. Targetoid bodies (signet ring-like
cells with eosinophil/basophil secretions, shown in
Fig. 1b), psammoma bodies (Fig. 1c), and open tumor
cell rings (rings of tumor cells without central stroma,
Fig. 1d) were presented in some cases. Tubulocysts
filled with mucinous secretions were observed in eight
cases, one of which with severe expansile tubulocysts
resembling thyroid follicles (Fig. 1e). Scattered nuclear
pseudoinclusions were noted in 6 cases (Fig. 1f ).
Endometriosis was observed in the specimen in 23.3 %
(17 of 73) of the cases.
Clinical parameters and survival (Table 2)
Follow-up information was obtained for 69 patients,
including 33 in stage I, 11 in stage II, 18 in stage III, and
7 in stage IV. The mean OS of each stage was as follows:
I, 85.3 months; II, 57.15 months; III, 31.5 months; and
IV, 30.1 months. Statistically significant differences in the
mean OS were observed (P < 0.001). The mean DFS of
each stage was as follows: I, 79.9 months; II, 45.4 months;
III, 24 months; and IV, 14 months. The differences in the
mean DFS were also significantly different (P < 0.001). The
survival of patients with stage I disease resulted in a
remarkably favorable prognosis compared with that of
patients in stages II–IV; we then analyzed the data from
the two groups in stages I and II–IV. The comparison of
DFS and OS between the patients in stages Ia/Ib and Ic
showed no statistically significant differences (P = 0.440
and P = 0.875, respectively).
Moreover, patients with ovarian CCC coexisting with
endometriosis were prone to develop unilateral tumors
(P = 0.038), with a trend of occurrence in relatively
younger patients (15 patients of < 60-year-old group vs.
2 patients of ≥ 60-year-old group, P = 0.062). Other
clinical parameters, such as age, tumor size, preoperative
CA125 level, ascites, and endometriosis, exhibited no
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significant difference in their association with DFS and
OS between groups (Table 2).
IMP3 immunohistochemical staining and survival
Forty-six of the 73 cases (63 %) showed positive IMP3
expression (Fig. 2a and 2b), and the remaining 27 cases
(37 %) were IMP3 negative.
The rate of IMP3 expression was significantly higher
in patients with an advanced stage (II–IV), with 73.0 %
positive cases (27 of 37), compared with the 52.8 % of
cases observed in stage I (19 of 36) (P = 0.046). The OS
was significantly shorter in IMP3-positive patients than
in those negative cases (55.8 months vs. 71.3 months,
P = 0.012, Fig. 3a), but no significant difference was
observed for DFS (P = 0.175). Upon further stratifica-
tion analysis of IMP3 expression in patients with stage
I, the IMP3-positive cases (23–133.6 months, mean
76.0 months) had a shorter OS than did the IMP3-
negative cases (11.2–173 months, mean 96.5 months)
(P = 0.038, Fig. 3b). None of the 17 IMP3-negative cases
of stage I died. However, 4 of 19 IMP3-positive cases
died from ovarian CCC metastasis, and their OS ranged
from 23.0 to 76 months (mean 40.4 months). Neverthe-
less, the DFS did not differ significantly between IMP3-
positive and IMP3-negative cases (P = 0.557). However,
no statistically significant differences in OS and DFS
were observed in patients with stage II-IV CCC (P =
0.892 and P = 0.840, respectively).
Discussion
Compared with common serous carcinomas, ovarian
CCC has distinct features such as poor prognosis and
platinum drug resistance. A relatively high percentage
of CCC cases are in stage I (31–-60 %) [20–23], which
is significantly higher than the percentage of patients
who have serous carcinoma (16.6–20 %) [3, 24]. Stage I
cases accounted for approximately 45.8–62.8 % of
Chinese CCC patients [25, 26]. The percentage of pure
CCC patients in stage I in the present study was 49.3 %
Fig. 1 a A solid nest is on the right, and the cystic morphology with columnar cells resembles an endometrial gland. b Targetoid bodies are signet ring-
like cells contained with eosinophil/basophil secretions. Classic hobnail cells can be observed in the top left corner. c Scattered psammoma bodies. d Open
tumor rings consist of a ring of tumor cells without a central fibrovascular stroma (A-D; original magnification, ×200). e Extremely expansive tubulocystic
morphology with mucinous secretions similar to a thyroid follicle (original magnification, ×40). f Nuclear pseudoinclusions were observed with severe cell
atypia, but mitotic figures were absent (original magnification, ×400)
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Table 2 The association of the clinical features and the expression of IMP3 with the prognosis of 73 patients with ovarian clear
cell carcinoma
DFS OS IMP3 expression Endometriosis
P P Positive Negative P Present Absent P
Age 0.097 0.071
≥60y 0.084 0.073 17 5 2 19
<60y 29 22 15 36
Tumor size 0.222 0.415
≥15 cm 0.337 0.285 8 8 5 11
<15 cm 38 19 12 44
Lateral 0.786 0.038
Unilateral / / 37 21 40 17
Bilateral 9 6 15 0
CA125 0.115 0.375
Above normal 0.201 0.935 29 18 10 34
Normal 8 1 3 5
Ascites 0.347 0.521
Present 0.055 0.271 19 14 9 7
Absent 24 11 24 27
Endometriosis 0.352 / / /
Present 0.534 0.424 9 8
Absent 36 19
Necrosis 0.260 0.296
Present 0.377 0.499 16 13 5 24
Absent 30 14 12 31
Papillary component 0.188 0.631
Present 0.123 0.180 37 18 12 42
Absent 9 9 5 13
Mitotic figures (/10 HPF) 0.488 0.660
<10 0.712 0.947 40 24 12 44
≥10 6 2 1 6
Stage 0.074 0.038
I <0.001 <0.001 19 17 12 23
II–IV 27 10 5 32
DFS 44 18 0.175
OS 44 18 0.012
Fig. 2 a Focal and moderately positive staining for IMP3 expression. b Diffuse and strong IMP3-positive staining (original magnification, ×200)
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(36 of 73), which is similar to the percentages that have
been reported in other populations.
According to a report by Higasi et al., the five-year
DFS and OS rates of each stage of ovarian CCC were
84 % and 88 % (stage I), 57 % and 70 % (stage II), 25 %
and 33 % (stage III), and 0 % and 0 % (stage IV), respect-
ively [27]. The five-year OS rates of the patients in our
group were similar to those reported in other studies of
non-Chinese populations: 78.8 % (stage I), 45.5 % (stage
II), 27.8 % (stage III), and 0 % (stage IV). According to a
previous report of a Chinese population, the five-year
OS rate of patients with stage I was 66.8 % [25]; the
survival rates in the current study were higher than
those in previous reports. A study by Hoskins et al. indi-
cated that the prognosis of patients with CCC in stage
Ia/Ib was more favorable than that of patients in stage Ic
[28] and that the prognosis of patients with stage Ic was
closer to that of patient with stage II [29]. However, OS
and DFS rates did not significantly differ between stages
Ia/Ib and Ic in this group; this result was comparable to
the report by Hoskins et al.
Ovarian CCC is closely related to endometriosis,
which was found in 23.3 % of our cohort. This value is
similar to the frequency of 26.8 % reported in another
Chinese population [26] but lower than that reported in
other countries (approximately 45 %) [30, 31]. Scarfone
et al. reported that patients with CCC arising from
endometriosis are generally younger than those with
general CCC [32]. Our results indicate that CCC cases
coexisting with endometriosis also had a trend of occur-
rence among relatively younger patients and were often
unilateral, although few cases arose directly from endo-
metriosis. The presence or absence of endometriosis was
not related to prognosis in any case in our study or in a
previously reported study [32]; however, some studies
have observed a better prognosis in CCC-associated
endometriosis [33, 34].
Ascites were often observed during operation and
were a trend among the patients with an unfavorable
prognosis compared to patients without ascites with
respect to DFS (P = 0.055) but not OS (P = 0.271).
The classical morphology of ovarian CCC cases is
tubulocystic, solid and papillary or with an admixture of
differnt growth pattern [17]. In the present study, 72 %
of the cases contained papillary structures. A mixture of
clear cells and oxyphilic cells was the most common cell
type. The tumor stroma was often observed to be a
mixture of hyalinized, myxoid, or fibroblastic types,
whereas pure hyalinization or pure myxoid stroma was
uncommon. In our cases, the average mitotic index was
4.6/10 HPFs, with most cases being lower than 10/10
HPFs (89 % of the group), which is quite consistent with
previous reports [31]. Furthermore, we did not observe
any statistically significant differences in the relationship
between morphology and prognosis.
The importance of IMP3 expression in the female re-
productive system is controversial. One study suggested
that IMP3 was a prognostic marker in metastatic ovarian
cancer [35], Kobel et al. suggested that IMP3 expression
was an independent indicator of a poor ovarian CCC
prognosis [12], and Noske et al. suggested that IMP3
expression was a marker of a good prognosis in ovarian
cancer (including serous carcinoma and non-serous
carcinoma) [15]. No further reports regarding IMP3 as a
prognostic biomarker have been published. The present
study demonstrated that IMP3 expression is closely
related to an unfavorable prognosis and that it may be
used as a potential indicator to estimate poor prognosis.
The results of our study are similar to those of Kobel et
al. In endometrial clear cell carcinoma, IMP3 was
Fig. 3 a The OS of the patients with positive IMP3 expression was worse than that of the negative cases among 73 cases. b The same trend was
observed in 36 cases with stage I disease
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reported to be closely correlated with poor prognosis
and relapse free survival (RFS) [13].
Furthermore, we analyzed the follow-up data of 33
patients with stage I CCC and found that IMP3 positiv-
ity was associated with a shorter OS (76.0 months vs.
96.5 months, P = 0.038). None of the 17 IMP3-negative
cases of stage I died, but 4 of 19 IMP3-positive cases
died from ovarian CCC metastasis. The results for the
5-year survival rate in our series show the same trend
reported by Kobel et al. Most ovarian CCC patients
received adjuvant chemotherapy after surgery. But for
those stage I patients, the benefit from chemotherapy
was not sufficient [36, 37]. However, the patients may
have, to endure severe side effects of chemotherapy.
IMP3, as a potential stratification prognostic factor in
stage I cases, may be used to stratify patients whom
may benefit from adjuvant therapy. However, IMP3+
tumors in stage I patients still have a wide range of sur-
vival (23–133.6 months) in our study. Thus, further
research are needed to verify the prognostic signifi-
cance of IMP3 in ovarian CCC. For example, studies
are needed to demonstrate whether IMP3 staining
correlates well with molecular tests for IMP3 expres-
sion, and furthermore, that IMP3 expression by mo-
lecular test correlates with prognosis.
It had been reported that knockdown of IMP3 in cer-
vical cancer, breast cancer and melanoma cell lines could
reduce cell migration and invasiveness [38–40]. In renal
cell carcinoma, IMP3 can also promote cell migration
and invasion by activation of NF-κB pathway [41]. As
recently reported, knockdown of IMP3 decreased cell
proliferation, migration, and invasion, and increased the
sensitivity to platinum in ovarian cancer through in-
creased expression of hCTR1 [42]. We presume that the
overexpression of IMP3 can increase the resistance to
platinum, which may lead to poor prognosis in ovarian
CCC, but further study is required.
Conclusion
In conclusion, we demonstrated that tumor stage and
IMP3 expression are prognostic indicator in ovarian
CCC. IMP3 overexpression is a potential marker of poor
prognosis for ovarian CCC, even in stage I. More studies
are required to further clarify the mechanism of IMP3
expression and its significance in ovarian CCC.
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